NetScientific plc (LON:NSCI): In January Glycotest announced that it had completed a 149-person Chinese retrospective study of its test for hepatocellular carcinoma (HCC). It demonstrated 93% sensitivity at 92% specificity, which is superior to the commonly used alpha-fetoprotein (AFP) test. Additionally, ProAxsis announced continued commercial progress with the CE mark of a ProteaseTag research kit for a new enzyme, plasmin, which may have utility in inflammatory conditions of the lung.
Glycotest excels in hard to find HCC
The recent clinical results confirmed those from earlier studies that demonstrated that the HCC test could efficiently identify 86% of patients who were missed by an AFP test and even 78% of those who were AFP negative in the early stage disease cohort. This supports the commercial proposition for the test because the ability to catch more patients at an earlier stage will allow them to be treated surgically and significantly reduce downstream costs.
To read the entire report Please click on the pdf File Below: